Verkauf durch Sack Fachmedien

Bonavida / Verma

Resistance to Immunotoxins in Cancer Therapy

Medium: Buch
ISBN: 978-3-319-17274-3
Verlag: Springer International Publishing
Erscheinungstermin: 27.06.2015
Lieferfrist: bis zu 10 Tage
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Produkteigenschaften


  • Artikelnummer: 9783319172743
  • Medium: Buch
  • ISBN: 978-3-319-17274-3
  • Verlag: Springer International Publishing
  • Erscheinungstermin: 27.06.2015
  • Sprache(n): Englisch
  • Auflage: 2015
  • Serie: Resistance to Targeted Anti-Cancer Therapeutics
  • Produktform: Gebunden, HC runder Rücken kaschiert
  • Gewicht: 5266 g
  • Seiten: 249
  • Format (B x H x T): 160 x 241 x 21 mm
  • Ausgabetyp: Kein, Unbekannt

Autoren/Hrsg.

Herausgeber

Bonavida, Benjamin

Verma, Rama Shanker

1 Targeted Cancer Therapy: History and Development of Immunotoxins.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins.-4 Cell Signaling and Resistance to Immunotoxins.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins.-9 Therapeutic Impact of Immune Responses in Cancer.